miR-34a synthetic mimics trigger growth inhibition and apoptosis in multiple myeloma cells by down-regulating canonical targets, Bcl-2, CDK6, and NOTCH1, both in vitro and in vivo [53]. The gene discussed is BCL2; the disease is plasma cell myeloma.